| Revenue growth | 8.3% YoY; 12.7% 5-year CAGR. |
|---|---|
| Margins | EBITDA at 24.4%; PBT margin improved to 21.2%. |
| Demand visibility | Strong growth in chronic and specialty therapy baskets. |
| Management confidence | High; citing market outperformance and consistent execution. |
Growth
Revenue grew 8.3%; EBITDA reached ₹172.7 cr (24.4% margin). Domestic formulations (69% of sales) grew 13.7%.
Outlook
Capex of ₹185+ cr over 5 years; focusing on specialty/chronic therapies and high-value synthetic APIs.
Risks
Regulatory compliance risks in 50+ markets and competitive intensity in the Indian Pharma Market.
Earnings Call filed with BSE, NSE: RPGLIFE. Summary written with AI assistance from the document.
RPG Life Sciences Ltd: key numbers
- Share price
- ₹3,050.60
- Market cap
- ₹5,045 Cr
- Revenue (annual)
- ₹707.5 Cr
- Net profit (annual)
- ₹115.2 Cr
- P/E (TTM)
- 42.2×Sector 50.4×
- Promoter holding
- 72.95%+0.00% QoQ
- FII holding
- 0.95%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from RPG Life Sciences Ltd
All →RPG Life Sciences Merger & Restructuring
RPG Life Sciences announced the amalgamation of its wholly-owned subsidiary, Actis Generics, into its other subsidiary, RPG Active Pharma Limited. No share exchange is involved.
RPG Life Sciences Acquisition
RPG Life Sciences completed its acquisition of the entire stake in Actis Generics Private Limited, making it a subsidiary of the company.
RPG Life Sciences Price Movement Clarification
RPG Life Sciences clarified that the recent increase in its trading volume is attributable to market conditions and there is no undisclosed price-sensitive information.
RPG Life Sciences Merger & Restructuring
RPG Life Sciences completed the slump sale of its API and intermediates business to Raghava Life Sciences Private Limited, effective September 16, 2026.
RPG Life Sciences Merger & Restructuring Worth ₹243.3 Cr
RPG Life Sciences' subsidiary, RPG Active Pharma, allotted shares to India Life Sciences Fund and Vistaject Fund for ₹243.33 crores. Post-allotment, RPG Active Pharma remains a subsidiary.
- Value
- ₹243.3 Cr
RPG Life Sciences Investor Presentation: Key Takeaways
RPG Life Sciences announced a strategic reorganization of its API business into a new subsidiary, RPGAP, involving a PE partnership and two bolt-on acquisitions to drive growth.